Guizhou Yibai Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of June 2025: 0.49%

Guizhou Yibai Pharmaceutical Co Ltd (600594) has an Asset Resilience Ratio of 0.49% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 600594 working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥20.00 Million

≈ $2.93 Million USD Cash + Short-term Investments

Total Assets

CN¥4.05 Billion

≈ $592.98 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2024–2024)

This chart shows how Guizhou Yibai Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Guizhou Yibai Pharmaceutical Co Ltd assets under control.

Liquid Assets Composition Over Time

This chart breaks down Guizhou Yibai Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Guizhou Yibai Pharmaceutical Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥20.00 Million	0.49%
Total Liquid Assets	CN¥20.00 Million	0.49%

Asset Resilience Insights

Limited Liquidity: Guizhou Yibai Pharmaceutical Co Ltd maintains only 0.49% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Guizhou Yibai Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Guizhou Yibai Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt F:RIG2	Drug Manufacturers - Specialty & Generic	0.20%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Beijing Tongrentang Co Ltd SHG:600085	Drug Manufacturers - Specialty & Generic	0.50%
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Changchun High & New Technology Industries Group Inc SHE:000661	Drug Manufacturers - Specialty & Generic	5.50%
Neuland Laboratories Limited NSE:NEULANDLAB	Drug Manufacturers - Specialty & Generic	9.65%
China Resources Double-Crane Pharmaceutical Co Ltd SHG:600062	Drug Manufacturers - Specialty & Generic	1.18%
Zhejiang Hisun Pharmaceutical Co Ltd SHG:600267	Drug Manufacturers - Specialty & Generic	0.01%

Annual Asset Resilience Ratio for Guizhou Yibai Pharmaceutical Co Ltd (2024–2024)

The table below shows the annual Asset Resilience Ratio data for Guizhou Yibai Pharmaceutical Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.49%	CN¥20.00 Million ≈ $2.93 Million	CN¥4.10 Billion ≈ $599.92 Million	--

pp = percentage points

About Guizhou Yibai Pharmaceutical Co Ltd

SHG:600594 China Drug Manufacturers - Specialty & Generic

Market Cap

$403.28 Million

CN¥2.76 Billion CNY

Market Cap Rank

#13413 Global

#3981 in China

Share Price

CN¥3.48

Change (1 day)

-4.92%

52-Week Range

CN¥2.95 - CN¥5.06

All Time High

CN¥19.64